eBook: The impact of therapeutic antibody discovery

Therapeutic antibodies

A new eBook, sponsored by Sino Biological, is now available for download entitled ‘The impact of therapeutic antibody discovery’.

The first monoclonal antibody (mAb), Orthoclone, was approved in 1986 to help prevent rejection in organ transplantation. Since then, the US Food and Drug Administration (FDA) has approved over 100 therapeutic antibodies.

The low toxicity and high specificity of antibodies make them an appealing target for clinical research and investment and the pace of discovery is only increasing. During 2023, 16 antibody therapeutics were granted approvals in the US or EU, either for the first time or for a new indication, covering uses as diverse as cancer, neurodegenerative diseases, diabetes and respiratory infections.

Download this exclusive eBook to learn more about:

  • How artificial intelligence and machine learning are benefitting antibody discovery and design
  • The potential impact of bispecific antibodies and antibody-drug conjugates
  • Methods to increase access to antigens and improve immunotherapy treatments
  • The role of therapeutic antibodies in the fight against Alzheimer’s disease

Read ‘The impact of therapeutic antibody discovery’ now.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free